Koers Immunoprecise Antibodies Ltd Other OTC
Aandelen
CA87588T1030
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 18,03 mln. 16,64 mln. | Omzet 2025 * | 29,82 mln. 21,87 mln. 20,18 mln. | Marktkapitalisatie | 39,83 mln. 29,21 mln. 26,95 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,8 mln. -8,12 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,6 mln. -6,09 mln. | EV/omzet 2024 * | 1,62 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,34 x |
K/w-verhouding 2024 * |
-3,16
x | K/w-verhouding 2025 * |
-4,28
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over Immunoprecise Antibodies Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,29% | 89,87 mld. | |
-3,95% | 37,57 mld. | |
-13,07% | 32,75 mld. | |
+63,05% | 26,47 mld. | |
-22,14% | 14,25 mld. | |
-7,96% | 12,99 mld. | |
-9,33% | 11,93 mld. | |
-46,33% | 10,84 mld. | |
+5,77% | 9,11 mld. |